The Goldline Pharmaceutical IPO has ended its bidding process on a very strong note, attracting massive investor interest across all categories. By the end of Day 3, the issue was subscribed 840.74 times, making it one of the most heavily oversubscribed IPOs in recent times.

What stood out in this IPO was not just the final number, but the way demand built up sharply in the last two days of bidding.

📊 Final Subscription Status (Day 3)

• Overall Subscription: 840.74×

• QIB (Qualified Institutional Buyers): 180.22×

• NII (High Net-worth Investors): 1,662.04×

• Retail Investors: 881.15×

• Total Applications: 1,66,595

📈 How the IPO Progressed Over 3 Days

The subscription didn’t explode immediately. Instead, it built up gradually and then surged at the end:

• Day 1: 22.35× – A decent but quiet start

• Day 2: 100.14× – Strong jump as interest picked up

• Day 3: 840.74× – A massive final-day rush

This kind of pattern usually shows that investors waited to see early response before aggressively jumping in during the last day.

🏦 What the Categories Tell Us

📌 QIB Response (180×)

Institutional investors subscribed over 180 times, which is a healthy sign. It suggests that bigger players see value in the company, though it’s not the highest institutional frenzy compared to some blockbuster IPOs.

📌 NII Segment (1,662×)

This is where the real action happened. The HNI category was heavily oversubscribed, showing strong leverage-based participation and aggressive bidding from high-net-worth investors.

📌 Retail Investors (881×)

Retail demand was also extremely strong. Many small investors participated, likely driven by momentum and positive market buzz.

🧠 What Does 840× Subscription Really Mean?

A subscription of this level usually indicates:

• Very high demand compared to available shares

• Extremely low chances of allotment for most applicants

• Strong listing-day expectations and hype

• Possible volatility after listing, depending on valuation comfort

However, it’s important to remember that oversubscription does not always guarantee strong long-term performance. It mainly reflects demand during the IPO window.

📌 Final Thoughts

The Goldline Pharmaceutical IPO clearly attracted widespread attention from all types of investors. The sharp jump in the final day shows how sentiment can build quickly in the IPO market when momentum kicks in.

Now all eyes will be on the allotment process and listing day performance, which will decide whether this heavy subscription translates into strong listing gains.